問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Obstetrics & Gynecology

更新時間：2024-06-03

呂建興Lu, Chien-Hsing
  • Principal Investigator
  • Clinical Trial Experience (year)

  • chlu@vghtc.gov.tw

Recruiting Trial

25Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

呂建興

List

42Cases

2018-09-01 - 2024-12-19

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

王鵬惠
Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2015-12-01 - 2026-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-08-31 - 2026-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2017-09-01 - 2023-04-20

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

王鵬惠
Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2021-06-25 - 2024-01-04

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-02-12 - 2030-07-31

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-07-01 - 2025-03-14

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2019-06-10 - 2024-04-24

Phase III

A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA)

  • Condition/Disease

    Locally Advanced Cervical Cancer

  • Test Drug

    Durvalumab

Participate Sites
6Sites

Terminated6Sites

2016-07-01 - 2019-12-24

Phase III

A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AND/OR FOLLOWING CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER

  • Condition/Disease

    Epithelial Ovarian Cancer

  • Test Drug

    MSB0010718C 20mg/ml Solution for Infusion

Participate Sites
7Sites

Terminated7Sites

王鵬惠
Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2016-11-01 - 2019-07-31

Phase III

A Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV

  • Condition/Disease

    High Risk Locally Advanced Cervical Cancer

  • Test Drug

    ADXS11-001

Participate Sites
6Sites

Terminated6Sites

張廷彰
Linkou Chang Gung Medical Foundation

Division of Obstetrics & Gynecology

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB